Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Rocket Pharmaceuticals Inc (NQ: RCKT)
24.82 USD  +1.29 (+5.48%)
Streaming Delayed Price  /  Updated: 4:00 PM EDT, Aug 3, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 222,041
Open 23.75
Bid (Size) 23.51 (1)
Ask (Size) 24.99 (1)
Prev. Close 23.53
Today's Range 23.37 - 24.84
52wk Range 9.010 - 27.59
Shares Outstanding 39,480,407
Dividend Yield N/A
Performance
YTD
+6.48%
+6.48%
1 Month
+10.75%
+10.75%
3 Month
+59.41%
+59.41%
6 Month
+18.59%
+18.59%
1 Year
+119.65%
+119.65%
Top News
More News
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that... Read More
from Business Wire News Releases
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that... Read More
from Business Wire News Releases
More News
Read More
Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021
from Business Wire News Releases
Rocket Pharmaceuticals Announces Participation at the Jefferies Virtual Healthcare Conference
from Business Wire News Releases
Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
from Business Wire News Releases
Rocket Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Progress
from Business Wire News Releases
Rocket Pharmaceuticals Announces Participation at the BofA Securities 2020 Health Care Conference
from Business Wire News Releases
How The Parts Add Up: DWAS Targets $60
category ETFs
from ETF Channel
Rocket Pharmaceuticals Appoints Elisabeth Bjӧrk, M.D., Ph.D. to Board of Directors
from Business Wire News Releases
Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic
from Business Wire News Releases
Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.